title: Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.
authors.affiliation: Nephropath, Little Rock, AR.
authors.forename: C L
authors.initials: CL
authors.lastname: Boils
authors.affiliation: University of Tennessee Medical Center, Knoxville, TN.
authors.forename: D N
authors.initials: DN
authors.lastname: Aljadir
authors.affiliation: University of Tennessee Medical Center, Knoxville, TN.
authors.forename: A W
authors.initials: AW
authors.lastname: Cantafio
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use; D006084:Graft Rejection / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D000077594:Nivolumab; D011241:Prednisone / Q000627:therapeutic use; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; D016572:Cyclosporine; D011241:Prednisone
keywords: cancer/malignancy/neoplasia: chemotherapy; clinical research/practice; immunosuppression/immune modulation; kidney (allograft) function/dysfunction; kidney transplantation/nephrology; organ transplantation in general; rejection; signaling/signaling pathways